Delfa

Delfa builds AI agents that automate patient recruitment for clinical trials, the single operational bottleneck behind much of trial cost and delay: with 22,000+ drug candidates in the pipeline but only about 5,000 new trials a year, more than a third of the cost comes down to finding, qualifying, and enrolling patients, still a manual funnel of Excel trackers, cold calls, and phone-collected histories. Delfa replaces that human bottleneck with agents trained on clinical trial documentation and guardrailed accordingly, which speak with patients in any language by phone, SMS, or chat to prescreen for medical eligibility, answer nuanced inclusion and exclusion questions, collect full medical histories (calls regularly run 20 minutes), book visits, and write directly into a site's CRM or CTMS. Quality is enforced heavily: every patient interaction is logged, reviewed, and scored across 20+ QA metrics, physicians audit outputs, and alerts fire in real time when something looks off. Because patients have opted in to trial contact, the use case is comparatively clean. Delfa already powers 50+ live trials with top site networks and has deployed production AI for J&J, Medtronic, and Exscientia. Reported outcomes include a migraine study site exceeding its enrollment target by 25% while saving 20 recruiter hours at an 11% lead-to-enrolled rate, and a vaccine trial where the agent matched human conversion. The company plans to build an AI-native CRM for patient recruitment on top of the voice wedge. $3.8M from Air Street.